Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets-Reference-Cited by-同舟云学术

Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets

Published:2014-09-17 Issue:9 Volume:7 Page:943-953
ISSN:1424-8247
Container-title:Pharmaceuticals
language:en
Short-container-title:Pharmaceuticals

Author:

Lammers Philip,Criscitiello Carmen,Curigliano Giuseppe,Jacobs Ira

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

http://www.mdpi.com/1424-8247/7/9/943/pdf

Reference25 articles.

1. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx

2. Cancer statistics, 2014

3. Cancer survival in five continents: a worldwide population-based study (CONCORD)

4. Breast Cancer: Prevention and Controlhttp://www.who.int/cancer/detection/breastcancer/en/index1.html

5. Herceptin US prescribing informationhttp://www.gene.com/download/pdf/herceptin_prescribing.pdf

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. QL1701 (a proposed trastuzumab biosimilar) versus reference trastuzumab plus docetaxel as first-line therapy for HER2-positive metastatic breast cancer: a multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial;ESMO Open;2024-09

2. Landscape of Subcutaneous Administration Strategies for Monoclonal Antibodies in Oncology;Advanced Materials;2024-08-20

3. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer;Cancers;2024-07-24

4. Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease;Expert Opinion on Biological Therapy;2024-07-02

5. Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study;Clinical Drug Investigation;2024-06-27